Designing a strategy to establish a best in class, end-to-end distribution & value chain for a novel gene therapy



Client Challenge

The client, a large pharmaceutical company was preparing for the launch of a gene therapy product. Client aimed to design and implement a value chain / distribution strategy to enable the delivery of its gene therapy product to patients. The distribution strategy needed to account for the implications of a low volume, high value product.

Conducted internal interviews to understand product specifications and key internal factors impacting likely distribution models. Facilitated a 'design principles' workshop to align on high level value chain model and initial strategic options. Hosted a 'labeling scenario' workshop to identify potential impacts of product's label on its value chain design

Project Phases

Conducted external interviews with physicians, pharmacists and health center support staff across key markets and analyzed qualitative insights to inform distribution strategy design. Facilitated cross-functional workshops to align on value chain decisions and distribution model design for product, data, and financial flows **Structured seven workstreams** with activity checklists for each workstream against a roadmap to guide timely implementation of the product's distribution strategy. Highlighted key workstream dependencies, expected outputs, capabilities to leverage, and teams involved to facilitate implementation plan

Outcome For The Client



Identification of critical decisions across value chain nodes and driving of key stakeholders to align upon decisions informing distribution




Outline of the product, data, and financial flows to support the delivery of the product from manufacturing site through patient administration



A structured implementation plan highlighting key activities for each function to execute to ensure product's distribution model was set up prior to launch







Implementation Plan

Implementation plan to guide execution of Drug X end-to-end value chain



Some or all of the services described herein may not be permissible for KPMG audit clients and their affiliates or related entities.

© 2022 KPMG LLP, a Delaware limited liability partnership and a member firm of the KPMG global organization of independent member firms affiliated with KPMG International Limited, a private English company limited by guarantee. All rights reserved. General Disclaimer: The information contained herein is of a general nature and is not intended to address the circumstances of any particular individual or entity. Although we endeavor to provide accurate and timely information, there can be no guarantee that such information is accurate as of the date it is received or that it will continue to be accurate in the future. No one should act upon such information of the particular situation of the particular situation. Independence Disclaimer: Some or all of the services described herein may not be permissible for KPMG audit clients and their affiliates or related entities.